Sack The DJ: Apple launches its new feature that can mix tracks using AI
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Apple has introduced a new feature to its iOS26 operating system that blends and mixes tracks together using AI.
It's called AutoMix and allows users to create 'unique transitions' between tracks, in the same manner of the DJ.
Of course, Spotify users have been able to crossfade between songs for some time. What's different with this new Apple feature is that it takes it a step further to allow "time stretching and beat matching to deliver continuous playback and an even more seamless listening experience."
There are other upgrades too. Also added is Lyrics Translation, which lets users understand the meaning of their favourite songs, and Lyrics Pronunciation, which enables users to sing along when lyrics are in another language.
So if you end up – for some reason - at a K Pop karaoke session, you'll no longer be scratching your head at how you're supposed to render the songs. According to Apple, the AI machine learning apparently ensures 'the emotion, cultural context, and lyrical intent are fully preserved.'
Meanwhile there's Sing, which allows users to convert the iPhone into a handheld microphone. Used in tandem with for Apple TV, it amplifies your voice you could can belt out your favourite songs with friends. With real-time lyrics and visual effects that light up the screen, Sing reaches a 'new level of fun' according to the people at Apple.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
6 minutes ago
- Gizmodo
This Battery-Powered Doorbell Now Costs Peanuts, Amazon Is Clearing Out Google's Stock
When it comes to home security and convenience, the battery-powered Google Nest Doorbell is a top choice for many and for good reason. This device offers the flexibility of battery power which makes it perfect for those who want a smart doorbell without the hassle of wiring—something especially appealing if you're not comfortable working with electrical systems. With this model, installation is as simple as mounting the device to your door frame and you're set. No drilling holes, no complicated wiring: just immediate, reliable access to (Wi-Fi) live video and smart alerts. It's this ease of use that has helped the Google Nest Doorbell consistently rank among the top 10 best-selling doorbells on Amazon, a testament to its popularity and effectiveness. Now, Amazon has cut the price of the battery-powered Google Nest Doorbell down to as little as $129 from the original launch price of $179. This battery model is especially attractive because it's for renters or whoever doesn't want to make any such permanent changes to their home. The battery life is amazing, typically months between recharging depending on usage, so you're not continually removing and plugging in the device. See at Amazon Easy to Use Doorbell The Google Nest Doorbell features that make it one of the smartest and simplest-to-use doorbells on the market. It has live HD video with HDR and night vision so you can watch what's happening at your door at any time. The camera's high vertical field of view makes it easy to capture individuals from head to foot or packages fallen on the floor and eliminates blind spots and not letting you miss anything. Doorbell is equipped with intelligence that enables it to detect people, packages, pets, and vehicles and send you customized notifications in the Google Home app – no subscription required. The device works with any door and you can even install it yourself in just minutes. If your Wi-Fi goes out or you lose electricity, the doorbell will buffer an hour of recorded events so you can always know what you missed. For additional needs, you can pay for a Nest Aware subscription (bought separately) to see as much as 60 days' worth of event video history, though note that the battery model doesn't come with constant 24/7 recording even in the event of a subscription. At its current price, it's one of the best deals you'll find for a smart doorbell. See at Amazon
Associated Press
11 minutes ago
- Associated Press
Braden Business Systems Honored with 2025 MSP Today Product of the Year Award
SmartOps Recognized for Exceptional Innovation and Real-World Impact Through the Channel Fishers, Indiana, United States, June 16, 2025 -- Braden Business Systems proudly announces that its proprietary IT operations platform, SmartOps, has been named a 2025 MSP Today Product of the Year Award winner by TMC. This prestigious award recognizes cutting-edge managed service solutions that empower organizations to enhance IT productivity, boost operational efficiency, and adapt to evolving technology demands. The MSP Today Product of the Year Award celebrates transformative products reshaping the managed services landscape. SmartOps earned this distinction for its innovative self-service capabilities, intelligent automation, and its ability to streamline day-to-day IT operations across diverse environments. SmartOps is Braden's AI-powered, web-based IT operations platform designed to empower users and IT teams alike. With SmartOps, businesses can perform tasks such as password resets, printer troubleshooting, application installations, and calendar permission changes through an intuitive self-service interface, eliminating the need to wait in helpdesk queues. It also provides on-demand access to Braden's expert IT professionals for troubleshooting, project planning, and technology procurement. Clients utilizing SmartOps have reported a productivity increase of over 50%. 'SmartOps is a testament to our belief that IT should be seamless, scalable, and empowering,' said Erik Braden, Managing Partner of Braden Business Systems. 'By reducing friction in everyday IT interactions and giving users the autonomy to resolve issues, SmartOps is redefining how businesses engage with their technology. We're honored that TMC recognizes the tangible value SmartOps brings to our clients and partners.' 'It gives me great pleasure to recognize Braden Business Systems as a 2025 recipient of TMC's MSP Today Product of the Year Award for their innovative solution, SmartOps,' said Rich Tehrani, CEO of TMC. 'Our judges were thoroughly impressed not only by the strength and features of the product, but by Braden's commitment to the Channel—empowering partners to deliver exceptional service and drive meaningful results for their clients.' Winners of the 2025 MSP Today Product of the Year Award will be featured on MSP Today, the definitive resource for managed service providers, as well as across TMCnet's media platforms. For more information about Braden Business Systems and SmartOps, visit About Braden Business Systems Braden Business Systems is a leader of business technology solutions, specializing in managed IT services, office equipment, cyber security and document management. Braden is ranked as the #1 MSP in Indiana and #172 nationally on the Channel Futures MSP 501 list; has been honored with placement on the Indiana Chamber's Top Ten Business list; and has won the Business Intelligence Group's Fortress Cybersecurity award for Leadership. For more information about Braden Business Systems, visit About MSP Today MSP Today is the premier online destination for MSPs (Managed Service Providers) and IT service providers worldwide. As the industry's leading web portal, we are committed to delivering timely and relevant news, cutting-edge product information, and invaluable insights to empower MSPs and IT professionals to thrive in today's rapidly evolving technology landscape. ABOUT TMC For more than 20 years, TMC has been honoring technology companies with awards in various categories. These awards are regarded as some of the most prestigious and respected awards in the communications and technology sector worldwide. Winners represent prominent players in the market who consistently demonstrate technological advancements. Each recipient is a verifiable leader in the marketplace. TMC Contact: Stephanie Thompson Manager, TMC Awards 203-852-6800 [email protected] About the company: Phone: +1 866-752-5961 Email: Contact Info: Name: Matthew Pitchford Email: Send Email Organization: Braden Business Systems Website: Release ID: 89162280 In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.
Associated Press
11 minutes ago
- Associated Press
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025-- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on CONTACT: Media Contact Information: Ned Glascock E-mail:[email protected] Website: Morton E-mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM
